Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


BLA Accepted: Novartis Inches Ahead In CAR-T Race With Kite

Executive Summary

Novartis may very well have the first CAR-T therapy approved in the US, beating its rival Kite Pharma to the finish line, since the FDA has accepted the Swiss big pharma's BLA for priority review. Kite says it will complete its rolling BLA submission in a different indication by the end of March.


Related Content

Cellectis Moves First Off-The-Shelf CAR-T Into US Clinical Trials
Killer Cures: Industry Heavyweights Make Their Presence Felt In Cell And Gene Therapy
Much Anticipated JULIET Data Show Novartis Playing Catch-Up On CAR-T Manufacturing
Bluebird Flies On 100% Response Rate For Anti-BCMA CAR-T
Novartis' CAR-T CTL019 Back On The Blockbuster Hit List
Juno Ends JCAR015 Development In ALL, Cementing Third Place CAR-T Position
Kite On Course For FDA Filing On Positive CAR-T Durability Data
Kite Flies CAR-T Into Asia With Daiichi Sankyo, Fosun Deals
ASH Ends With Consistent Kite CAR-T Data, Some Hope For Juno
Novartis, Kite Neck-And-Neck In CAR-T Race; Deaths Keep Juno In Third Place


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts